MedWatch

Orphazyme CEO silent on potential firings in wake of FDA rejection

The FDA rejection of Orphazyme's drug candidate in its main indication will trigger major cuts at the biotech firm, but CEO Christophe Bourdon has no comment on where they will be implemented and how hard the US organization will be hit.

Photo: Orphazyme / PR

Orphazyme will be scrutinizing its expenses after the US Food and Drug Authority, the FDA, rejected its main candidate arimoclomol for the treatment of the metabolic disease Niemann-Pick type C, also known as NPC.

According to Orphazyme's CEO Christophe Bourdon, the company has started looking into what will happen to the US organization, in which it has invested large sums in recent months in order to prepare for the potential launch. The rejection from the FDA, announced on Friday, has turned this into more of a long-term prospect.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs